Published in Ann N Y Acad Sci on April 05, 1997
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Rheumatoid arthritis. Cell (1996) 6.01
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol (1993) 3.33
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37
Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermatol (1998) 2.37
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Measurement of DNA antibodies by double antibody precipitation. Ann Rheum Dis (1973) 2.21
The Arthritis and Rheumatism Council's National Repository of Family Material: pedigrees from the first 100 rheumatoid arthritis families containing affected sibling pairs. Br J Rheumatol (1994) 2.14
The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med (1979) 2.07
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
The clinical significance of mediators of cellular immunity. Clin Allergy (1971) 2.03
Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J (1978) 2.01
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum (1985) 1.99
Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum (1995) 1.94
Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol (1997) 1.90
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Purification and characterization of the Sjögren's syndrome A and B antigens. Clin Exp Immunol (1983) 1.73
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis (1986) 1.66
Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis. Ann Rheum Dis (1980) 1.65
Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol (1991) 1.60
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol (1999) 1.58
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum (2004) 1.56
Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum (1996) 1.56
Murine lupus monoclonal antibodies define five epitopes on two different Sm polypeptides. Immunology (1986) 1.54
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol (1997) 1.53
Serological and immunogenetic markers of extraglandular primary Sjögren's syndrome. Br J Rheumatol (1993) 1.53
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum (1992) 1.53
DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol (1997) 1.52
Lymphocyte mitogenic factor in man. Nature (1969) 1.51
Titers of antibodies to RANA in rheumatoid arthritis and normal sera. Relationship to Epstein-Barr virus infection. Arthritis Rheum (1981) 1.49
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum (2000) 1.49
Quantitation and detection of isotypes of anti-SS-B antibodies by ELISA and Farr assays using affinity purified antigens. An approach to the investigation of Sjögren's syndrome and systemic lupus erythematosus. Arthritis Rheum (1983) 1.48
Immunogenic and antigenic epitopes of immunoglobulins. XVII--Monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors. Rheumatol Int (1986) 1.47
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Antibodies to extractable nuclear antigens in rheumatoid arthritis: relationship to vasculitis and circulating immune complexes. Clin Exp Immunol (1980) 1.47
Monoclonal antibodies to the Sjögren's syndrome associated antigen SS-B (La). J Immunol Methods (1985) 1.46
Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol (1997) 1.46
Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS (2000) 1.44
Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol (1992) 1.44
Expression of VHIII-associated cross-reactive idiotype on human B lymphocytes. Association with staphylococcal protein A binding and Staphylococcus aureus Cowan I stimulation. J Immunol (1991) 1.44
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A (1994) 1.42
A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2001) 1.41
Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis (1984) 1.41
Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol (1998) 1.40
Incidence of three cross-reactive idiotypes on human rheumatoid factor paraproteins. J Immunol (1988) 1.39
Standardization of the leucocyte migration test. Int Arch Allergy Appl Immunol (1973) 1.39
The association of cryoglobulinaemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor. Clin Exp Immunol (1979) 1.39
A novel PCR-RFLP assay for the detection of the single nucleotide polymorphism at position -1082 in the human IL-10 gene promoter. Eur J Immunogenet (2000) 1.39
Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J Clin Invest (1988) 1.38
Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis (1990) 1.38
Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum (2002) 1.38
Virus infection induces redistribution and membrane localization of the nuclear antigen La (SS-B): a possible mechanism for autoimmunity. Clin Exp Immunol (1989) 1.36
Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med (1995) 1.36
Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) (2000) 1.35
Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol (1999) 1.35
Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun (1989) 1.33
T cells expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun (1988) 1.32
Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis (1989) 1.31
The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.29
The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol (1992) 1.27
Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol (2000) 1.27
Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol (1998) 1.27
Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee. Tissue Antigens (2001) 1.27
The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun (2001) 1.26
Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol (1997) 1.26
High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum (1995) 1.26
Coordinate expansion of 'fetal type' lymphocytes (TCR gamma delta+T and CD5+B) in rheumatoid arthritis and primary Sjögren's syndrome. Clin Exp Immunol (1989) 1.25
HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. J Rheumatol (2001) 1.25
Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol (1997) 1.23